PSAT385 Single Center Experience with the Combination of Lenvatinib and Pembrolizumab for the Treatment of Anaplastic Thyroid Cancer

INTRODUCTION: Anaplastic thyroid cancer (ATC) is rare with a poor prognosis. There are no approved treatments for non-BRAF-mutated ATCs, leading to an unmet need. Phase II studies of single-agent lenvatinib or immunotherapy showed minimal benefit (lenvatinib: overall response rate (ORR) 2.9%, progre...

Descripción completa

Detalles Bibliográficos
Autores principales: Vodopivec, Danica M, Cabanillas, Maria E, Busaidy, Naifa L, Gule-Monroe, Maria K, Zafereo, Mark E, Wang, Jennifer R, Williams, Michelle D, Waguespack, Steven G, Bassett, Roland, Maniakas, Anastasios, Lai, Stephen Y, Dadu, Ramona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Thyroid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628971/
http://dx.doi.org/10.1210/jendso/bvac150.1754

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628971/
http://dx.doi.org/10.1210/jendso/bvac150.1754

Ejemplares similares